peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update

20 Jan 2022, 08:00

Lund, Sweden January 20, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-End report 2021 at 8:00 CET on February 3, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-End results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 850 55 83 51

United Kingdom: +44 333 300 92 60

United States: +1 646 722 49 56

The webcast will be available on

Updated Calendar and Events 2022

Feb 3, 2022                  Year-End report for Jan - Dec 2021

Mar 10, 2022                Erik Penser Bolagsdag, Stockholm

Mar 10, 2022                Redeye Investor Forum, Gothenburg

Mar 15, 2022                Carnegie Healthcare Seminar 2022, Stockholm

Mar 31, 2022                Redeye Investor Forum, Malmö

April 7, 2022                 Annual Report 2021 

April 21, 2022               Interim Report for January-March 2022

April 21, 2022               Kempen Life Sciences Conference 2022, Amsterdam

April 27, 2022               Redeye Orphan Drugs 2022, Stockholm

May, 2022                     RBC Global Healthcare Conference 2022, New York City

June 16, 2022               Annual General Meeting 2022

July 21, 2022                Half year 2022 report 

Oct 20, 2022                 Interim Report for January-September 2022

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at